The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries

Coronary Artery Disease Clinical Trial

— VANTAGE-1  

Official title:

The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01025869
• Other study ID #: 902
• Status: Terminated
• Phase: N/A
• First received: December 3, 2009
• Last updated: January 8, 2016
• Start date: December 2009
• Est. completion date: March 2012

Study information

• Verified date: January 2016
• Source: Atrium Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: New Zealand: Health and Disability Ethics Committees
• Study type: Interventional

Clinical Trial Summary

To investigate the safety and efficacy of the Cinatra™ Corolimus Drug Eluting Stent for the treatment of de novo lesions in native coronary arteries.

Description:

This is a single-arm, multicentre pilot study designed to provide an indication of the effectiveness and safety of the Cinatra™ Corolimus Eluting Coronary Stent System. The primary endpoint to be evaluated in this study is late lumen loss (in-stent) at 6 months post-procedure as measured by QCA in the 30 participants undergoing angiography at this timepoint. Late lumen loss is defined as the difference between the post-index procedure minimal lumen diameter (MLD) and the follow-up MLD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 31
• Est. completion date: March 2012
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is = 18 years old

2. Patient is an acceptable candidate for percutaneous coronary intervention (PCI), stenting, and emergent coronary artery bypass graft (CABG) surgery

3. Patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, and/or a positive functional study

4. Female subjects of childbearing potential must have a negative pregnancy test within 7 days before the trial procedure

5. Patient or subject's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the Hospital Research Ethics Committee (HREC) of the respective investigational site

6. Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed

Angiographic:

1. Patient has either a single target lesion, or two lesions (target and non-target) located in separate coronary arteries

2. If a non-target lesion is treated, it must be treated first and only with commercially available PTCA balloons and/or stents. Post PCI of the non-target vessel, all of the following conditions must be met:

• Residual diameter stenosis <10%

• Absence of any angiographic complications

• Absence of ischaemic symptoms

• Absence of significant new arrhythmia or ECG monitoring changes suggestive of ischaemia

3. Target lesion must be a de novo lesion in native coronary artery

4. Target lesion must be = 22 mm in length

5. Target lesion must have a stenosis of = 50% and < 100%

6. Target vessel must have a reference vessel diameter (RVD) appropriate for treatment with a of 3.0mm or3.5 mm stent

7. Target vessel must have a Thrombolysis in Myocardial Infarction (TIMI) flow = 2

Exclusion Criteria:

1. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, chromium, stent coatings (i.e. fatty acids, glycerides, and alpha tocopherol), or a sensitivity to contrast media, which cannot be adequately pre-medicated

2. History of an allergic reaction or significant sensitivity to drugs such as , zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative

3. Platelet count < 100,000 cells/mm³ or > 700,000 cells/mm³, or a white blood cell (WBC) count < 3,000 cells/mm³ within 7 days prior to index procedure

4. Serum creatinine level 170 micromol/L within 7 days prior to index procedure

5. Evidence of an acute myocardial infarction (MI) within 72 hours of the intended trial procedure (defined as: Q wave myocardial infarction (QWMI) or non-Q wave myocardial infarction (NQWMI) having CK enzymes > 2X the laboratory upper limit of normal with the presence of an elevated CK-MB (any amount above the laboratory upper limit of normal)

6. Previous PCI of the target vessel within 9 months prior to the procedure

7. Any planned additional PCI procedure within 30 days post-index procedure and/or planned PCI of the target vessel within 12 months post-procedure

8. During the index procedure, the target and/or non-target lesion(s) requires treatment with a device other than PTCA prior to stent placement (including, but not limited to, cutting balloon, atherectomy, thrombectomy, etc.)

9. Left ventricular ejection fraction (LVEF) < 30% if evaluated, or clinical evidence of significant congestive heart failure (NYHA Class III or IV) within the prior 30 days

10. History of a stroke or transient ischemic attack (TIA) within the prior 6 months

11. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months

12. History of bleeding diathesis or coagulopathy or will refuse blood transfusions

13. Concurrent medical condition with a life expectancy of less than 12 months

14. Any previous treatment of the target vessel(s) for restenosis, including brachytherapy

16. Any condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study 17. Currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures

Angiographic:

1. Target lesion is located in native vessel distal to anastomosis with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass with more than 40% diameter stenosis anywhere within the graft

2. Previous stenting in the target vessel.

3. The target vessel has other lesions with greater than 40% diameter stenosis based on visual estimate or on-line QCA

4. The target vessel has evidence of thrombus

5. The target vessel is excessively tortuous (two bends > 90º to reach the target lesion)

6. The target lesion has any of the following characteristics:

• Lesion location is aorto-ostial, an unprotected left main lesion, or within 5 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX)

• Involves a side branch > 2.0 mm in diameter

• Is at or distal to a > 45º bend in the vessel

• Is severely calcified

7. Unprotected left main coronary artery disease (an obstruction greater than 50% in the left main coronary artery)

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• Cinatra™ Corolimus Eluting Coronary Stent System
Stent implantation

Locations

Country	Name	City	State
New Zealand	Auckland City Hospital	Auckland
New Zealand	Mercy Angiography	Auckland
New Zealand	North Shore Hospital	Auckland
New Zealand	Christchurch Hospital	Christchurch

Sponsors (1)

Lead Sponsor	Collaborator
Atrium Medical Corporation

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In-stent late lumen loss (LLL) as measured by quantitative coronary angiography (QCA).		6 months post treatment	No
Secondary	Target lesion revascularization		1, 6 and 18 month and annually to 5 years	No
Secondary	Target vessel revascularization		1 month and at all follow up to 5 years	No
Secondary	Stent thrombosis		All follow ups	Yes
Secondary	Neointimal Hyperplasia		6 and 18 months	No
Secondary	Binary restenosis		6 and 18 months	No
Secondary	MACE (Major Adverse Cardiac Event)		1 month, 6 month, 18 month and annually to 5 years	Yes
Secondary	In-segment late lumen loss (LLL) as measured by quantitative coronary angiography		6 and 18 months	No
Secondary	In-stent late lumen loss (LLL) as measured by quantitative coronary angiography		18 months (optional)	No
Secondary	Minimal Lumen Diameter (MLD), in-stent and in-segment		6 and 18 months	No
Secondary	Rates of incomplete stent apposition		6 and 18 months	No
Secondary	Device success defined as achievement of a final residual diameter stenosis of < 30% measured by QCA, using the study device only.		procedure	No
Secondary	Lesion treatment success is defined as <30% residual stenosis measured by QCA by any treatment		Procedure	No
Secondary	Procedure success defined as lesion success without the occurrence of MACE during the hospital stay		discharge	Yes